Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Forum for Health Economics & Policy

Editor-in-Chief: Goldman, Dana


CiteScore 2017: 0.53

SCImago Journal Rank (SJR) 2017: 0.425
Source Normalized Impact per Paper (SNIP) 2017: 0.297

Online
ISSN
1558-9544
See all formats and pricing
More options …

A Primer on the Economics of Prescription Pharmaceutical Pricing in Health Insurance Markets

Ernst R. Berndt
  • 1Massachusetts Institute of Technology and National Bureau of Economic Research, eberndt@ mit.edu
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Thomas McGuire / Joseph P. Newhouse
Published Online: 2011-11-07 | DOI: https://doi.org/10.2202/1558-9544.1301

The pricing of medical products and services in the U.S. is notoriously complex. In health care, supply prices (those received by the manufacturer) are distinct from demand prices (those paid by the patient) due to health insurance. The insurer, in designing the benefit, decides what prices patients pay out-of-pocket for drugs and other products. In this primer we characterize cost and supply conditions in markets for generic and branded drugs, and apply basic tools of microeconomics to describe how an insurer, acting on behalf of its enrollees, would set demand prices for drugs. Importantly, we show how the market structure on the supply side, characterized alternatively by monopoly (unique brands), Bertrand differentiated product markets (therapeutic competition) and competition (generics), influences the insurer’s choices about demand prices. This perspective sheds light on the choice of coinsurance versus copayments, the structure of tiered formularies, and developments in the retail market.

Keywords: pharmaceuticals; health insurance; prices; Bertrand competition; brands; generics

About the article

Published Online: 2011-11-07


Citation Information: Forum for Health Economics & Policy, Volume 14, Issue 2, ISSN (Online) 1558-9544, DOI: https://doi.org/10.2202/1558-9544.1301.

Export Citation

©2012 Walter de Gruyter GmbH & Co. KG, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[2]
Ya-Chen Tina Shih, Ying Xu, Lei Liu, and Fabrice Smieliauskas
Journal of Clinical Oncology, 2017, Volume 35, Number 22, Page 2482
[3]
Anirban Basu, Prasun Subedi, and Sachin Kamal-Bahl
Value in Health, 2016, Volume 19, Number 6, Page 861
[5]
Abby Alpert, Mark Duggan, and Judith K. Hellerstein
Journal of Public Economics, 2013, Volume 108, Page 44

Comments (0)

Please log in or register to comment.
Log in